Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by TriumphSpitSixon Apr 02, 2019 7:38pm

189 Views

Post# 29573171

RE:RE:RE:What happended to

Yes, full therapeutic initial dose AND a follow-up treatment at 6 mos just for good measure, although today's results indicate it probably isn't necessary in most patients.

Certainly can't hurt though to ensure there is no latent cancerous tissue in areas too small to be detected that could re-emerge later.

There's probably a better "medically-precise" way to say that but hopefully you get the idea.

rp2298 wrote:

nemo3 wrote: Patients 1 to 3 only received half a dose. That wasn't enough. It shows all the info on their website.

So for PH2, I presume all the patients will be recieving the full dose that P5 and P6 got?